Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 05 April 2018

Indication(s)

- Myclausen 500 mg film-coated tablets

Myclausen is indicated in adults, and children and adolescents aged 2 to 18 years in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.
 

- Myclausen 250 mg hard capsules

Myclausen is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Transplantation

Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Fluid Management

Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

+ 2 more

Hereditary ATTR amyloidosis

Hereditary ATTR amyloidosis

Explore the pathophysiology, epidemiology and multi-system symptoms associated with hereditary ATTR amyloidosis, as well as how to achieve an early and accurate diagnosis.

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/001218
Orphan designation No
Date First Approved 07-10-2010
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Passauer Pharma GmbH